Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.855
-0.055 (-2.88%)
At close: Sep 25, 2026, 4:00 PM EDT
1.890
+0.035 (1.89%)
After-hours: Sep 25, 2026, 7:59 PM EDT
Autolus Therapeutics Employees
As of December 31, 2025, Autolus Therapeutics had 754 total employees, including 752 full-time and 2 part-time employees. The number of employees increased by 104 or 16.00% compared to the previous year.
Employees
754
Change (1Y)
104
Growth (1Y)
16.00%
Revenue / Employee
$155,690
Profits / Employee
-$371,560
Market Cap
493.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 754 | 104 | 16.00% | 752 | 2 |
| Dec 31, 2024 | 650 | 179 | 38.00% | 647 | 3 |
| Dec 31, 2023 | 471 | 67 | 16.58% | 463 | 8 |
| Dec 31, 2022 | 404 | 77 | 23.55% | 399 | 5 |
| Dec 31, 2021 | 327 | -57 | -14.84% | 324 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Arvinas | 246 |
| ProKidney | 231 |
| Capricor Therapeutics | 231 |
| Puma Biotechnology | 179 |
| Assembly Biosciences | 73 |
| AgomAb Therapeutics NV | 62 |
| Eupraxia Pharmaceuticals | 49 |
AUTL News
- 2 days ago - Autolus Therapeutics management to meet virtually with William Blair - TheFly
- 12 days ago - Autolus Therapeutics Registration statement: Registration filing - Filings
- 12 days ago - Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders - TheFly
- 17 days ago - Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel - TheFly
- 17 days ago - Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis - GlobeNewsWire
- 5 weeks ago - Autolus Therapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - Autolus Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - Autolus Therapeutics Earnings release: Q2 2026 - Filings